Rgenta Therapeutics Announces Formation of Repeat Expansion Diseases Focused Scientific Advisory Board
Retrieved on:
Wednesday, June 21, 2023
UK Academy for Information Systems, SAB, Huntington's disease, New England, DNA, Myotonic Dystrophy Foundation, Muscular dystrophy, Disease, Pathology, Research, Brain, Department of Neurology, Xuanwu hospital, RNA, Genome, Boston University, Science, Human genetics, Gene silencing, Genetics, Facioscapulohumeral muscular dystrophy, Virginia Commonwealth University, Neurology, Knowledge, Ghana Infectious Disease Centre, Reds, Therapy, Gene, NIH, Myotonic dystrophy, ALS, Fragile X syndrome, DNA repair, Pharmaceutical industry, Chobanian, Medicine
CAMBRIDGE, Mass., June 21, 2023 /PRNewswire/ -- Rgenta Therapeutics today announced the formation of a Repeat Expansion Diseases (REDs) Focused Scientific Advisory Board (REDs SAB).
Key Points:
- CAMBRIDGE, Mass., June 21, 2023 /PRNewswire/ -- Rgenta Therapeutics today announced the formation of a Repeat Expansion Diseases (REDs) Focused Scientific Advisory Board (REDs SAB).
- REDs SAB is an esteemed group of preclinical and clinical experts who contribute to basic and translational research on the mechanisms and treatments for repeat expansion diseases.
- "We are proud and honored to introduce our REDs focused SAB," said Dr Zhiping Weng, Rgenta SAB chair.
- "Their knowledge and insights to the repeat expansion diseases will help advance the preclinical and clinical development of our small molecule programs."